Kyverna Therapeutics, Inc. Common Stock (KYTX)

Kyverna Therapeutics, Inc. Common Stock (KYTX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $395M; returns 1 day -5.9%, 1 week -4.9%, 1 year -15.8%.

Kyverna Therapeutics, Inc. (KYTX) is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Their lead product candidate is KYV-101 (miv-cel or mivocabtagene autoleucel), an autologous CD19 CAR T-cell product.

Groups KYTX belongs to

• Clinical Stage Biotech
• Autoimmune Diseases
• Biotechnology
• Biopharmaceutical
• Healthcare
• Clinical Stage
• Clinical Stage Biopharma
• Autologous Cell Therapy
• Immunotherapy
• Biologics
• Life Sciences
• Chronic Inflammatory Diseases

KYTX financial model: income statement, cash flow and balance sheet